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OBJECTIVES The possible role of the ATP-sensitive potassium (KATP) channel in cardioprotection by
Na1-H1 exchange (NHE) inhibition was examined.
BACKGROUND The KATP channel is suggested to be involved not only in ischemic preconditioning but also
in some pharmacological cardioprotection.
METHODS Infarction was induced by 30-min coronary occlusion in rabbit hearts in situ or by 30-min
global ischemia in isolated hearts. Myocardial stunning was induced by five episodes of 5-min
ischemia/5-min reperfusion in situ. In these models, the effects of NHE inhibitors (cariporide
and ethylisopropyl-amiloride [EIPA]) and the changes caused by KATP channel blockers were
assessed. In another series of experiments, the effects of EIPA on mitochondrial KATP
(mito-KATP) and sarcolemmal KATP (sarc-KATP) channels were examined in isolated
cardiomyocytes.
RESULTS Cariporide (0.6 mg/kg) reduced infarct size in situ by 40%, and this effect was abolished by
glibenclamide (0.3 mg/kg), a nonselective KATP channel blocker. In vitro, 1 mM cariporide
limited infarct size by 90%, and this effect was blocked by 5-hydroxydecanoate (5-HD), a
mito-KATP channel blocker but not by HMR1098, a sarc-KATP channel blocker. Infarct size
limitation by 1 mM EIPA was also prevented by 5-HD. Cariporide attenuated regional
contractile dysfunction by stunning, and this protection was abolished by glibenclamide and
5-HD. Ethylisopropyl amiloride neither activated the mito-KATP channel nor enhanced
activation of this channel by diazoxide, a KATP channel opener.
CONCLUSIONS Opening of the mito-KATP channel contributes to cardioprotection by NHE inhibition,
though the interaction between NHE and this KATP channel remains unclear. (J Am Coll
Cardiol 2001;37:957–63) © 2001 by the American College of Cardiology
The Na1-H1 exchanger type 1 (NHE-1) is an important
acid excluder in cardiomyocytes, and its contribution to
ischemic myocardial injury has been indicated by consistent
observation that administration of NHE-1 inhibitors before
ischemia reduces infarct size, myocardial stunning and
arrhythmia (1–6). A current hypothesis proposes that inhi-
bition of NHE-1 reduces intracellular Na1 accumulation in
ischemic myocytes, which consequently results in less Ca11
overload via the Na1-Ca11 exchanger and, thus, less
cellular injury. This hypothesis is supported by the results of
studies using nuclear magnetic resonance spectroscopy (4–
6), which showed ischemia-induced elevation in cytosolic
Na1 and Ca11 levels was significantly delayed by amiloride,
ethylisopropyl amiloride (EIPA) and cariporide, a specific
NHE-1 inhibitor. However, amiloride derivatives also in-
hibit the Na1-Ca11 exchanger (7) and Na1 channel (8).
Cytosolic Ca11 overload during simulated ischemia was not
prevented by hexamethylene amiloride (9) nor by cariporide
(10) in isolated cardiomyocytes. Therefore, the suppression
of cytosolic Ca11 overload may not be an exclusive mech-
anism of cardioprotection by NHE-1 inhibition.
Recent studies (11–16) have demonstrated that myocar-
dial tolerance against ischemia/reperfusion injury is en-
hanced by activation of the KATP channel. This channel has
received attention as a trigger as well as a mediator of
anti-infarct tolerance in the mechanism of ischemic precon-
ditioning (11–14). Furthermore, two independent studies
suggest that KATP channels may be involved also in phar-
macological cardioprotection (15,16). Therefore, in this
study, we used inhibitors of the mitochondrial KATP (mito-
KATP) and sarcolemmal KATP (sarc-KATP) channels to
examine the role of the KATP channel and its relevant
channel subtype in cardioprotection afforded by NHE
inhibition. In addition, interaction of NHE inhibition and
the mito-KATP activity was assessed in isolated cardiomyo-
cytes.
METHODS
Experiment 1: effects of KATP channel blockers on infarct
size-limiting effects of cariporide in vivo. SURGICAL PREP-
ARATION. Male albino rabbits (Japanese white) weighing
2.0 to 2.5 kg were prepared to induce myocardial infarction
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in vivo as in our previous studies (2,17). In brief, a coronary
snare was placed around the marginal branch of the left
coronary artery after left thoracotomy under pentobarbital
anesthesia and mechanical ventilation. Blood pressure mon-
itoring and drug injections were performed by using cath-
eters placed in the carotid artery and the jugular vein,
respectively. Precordial electrocardiogram was monitored by
bipolar electrodes on the chest.
EXPERIMENTAL PROTOCOLS. Rabbits were divided into
four groups and underwent 30-min coronary occlusion and
3-h reperfusion. The cariporide group received 0.6 mg/kg of
cariporide 10 min before the coronary occlusion, and the
glibenclamide group was given 0.3 mg/kg of glibenclamide
20 min before ischemia. The glibenclamide/cariporide
group received the same doses of glibenclamide and caripo-
ride, which were injected at 20 and 10 min before ischemia,
respectively. In the control group, only saline was injected.
After 3 h of reperfusion, the heart was excised and processed
for postmortem analysis of infarct size.
POSTMORTEM ANALYSIS OF THE HEART. As in previous
studies (2,17), the excised heart was quickly mounted onto
a Langendorff apparatus and perfused with saline. The
coronary artery was reoccluded, and Evans Blue dye was
injected into the perfusion line to negatively mark the
territory of the marginal branch (i.e., area at risk). The heart
was sectioned into 2-mm slices, stained by triphenyltetra-
zolium chloride (TTC), and infarct and risk areas were
determined by computer-assisted planimetry.
Experiment 2: effects of KATP channel subtype selective
blockers on infarct size-limiting effects of NHE inhibi-
tors in vitro. SURGICAL PREPARATION. Using rabbits
weighing 1.8 to 2.1 kg, isolated heart preparation was
prepared as previously reported (13). Isolated rabbit hearts
were perfused with oxygenated modified Krebs-Henseleit
buffer (NaCl, 118.5 mM; KCl, 4.7 mM; NaHCO3,
24.8 mM; KH2PO4, 1.2 mM; MgSO4, 1.2 mM; CaCl2,
2.5 mM; glucose, 10.0 mM). Perfusion pressure and tem-
perature of the perfusate were 75 mm Hg and 37°C,
respectively. A 3Fr catheter tip manometer (SPR-524,
Millar Instruments Inc., Houston, Texas) was inserted into
the left ventricle (LV), and coronary flow was measured by
collection of coronary effluent in a graduated cylinder. The
heart was excluded from the study if the LV developed
pressure (LVDP) was ,70 mm Hg or arrhythmias were
observed after a 15-min stabilization period.
EXPERIMENTAL PROTOCOLS. Myocardial infarction was
induced by 30-min global ischemia and 2-h reperfusion as
in a previous study (13). Although this reperfusion period
was shorter than in experiment 1, infarcts were clearly
identified by TTC staining, presumably because higher
coronary flow in vitro facilitated dehydrogenase washout
from necrotic tissues. In protocol 1, the hearts received one
of the following six pretreatments for 10 min before the
30-min ischemia: no drug (i.e., controls), 1 mM cariporide,
50 mM 5-hydroxydecanoate (5-HD), 1 mM cariporide plus
50 mM 5-HD, 20 mM HMR1098 and 1 mM cariporide
plus 20 mM HMR1098. HMR1098 is Na1 salt of
HMR1883, a selective blocker of sarc-KATP channels (18),
and 5-HD is a selective blocker of mito-KATP channels
(19). In protocol 2, the hearts received one of the following
four pretreatments: no drug (i.e., controls), 1 mM ethyliso-
propyl amiloride (EIPA), 100 mM 5-HD and a combina-
tion of both agents for 10 min of the preischemic period.
The dose of 5-HD was increased to 100 mM in this
protocol since the effect of 50 mM 5-HD on EIPA-induced
cardioprotection was found to be variable in pilot experi-
ments. At the end of the experiments, each heart was sliced,
and infarct size was identified by TTC staining as in
experiment 1. The uppermost slices, which contained valves
and the perivalvular connective tissues, were excluded from
subsequent analysis. The LV area (i.e., area at risk) and
infarcts in the LV were measured by computer-assisted
planimetry.
Experiment 3: effects of KATP channel blockers on
antistunning effects of cariporide. SURGICAL PREPARA-
TION. Rabbits were instrumented for measuring regional
and global ventricular functions in vivo as previously re-
ported (20). A catheter-tipped manometer was placed in the
LV, and the first derivative of LV pressure (LV dP/dt) was
obtained by electronic differentiation. A coronary snare was
placed around the marginal branch of the left coronary
artery, and an epicardial Doppler sensor was secured to the
epicardium in the region of the marginal branch. This
sensor was connected to a Pulsed Doppler Dimension
System VF-1 (Crystal Biotec, Hopkinton, Minnesota) to
determine regional wall thickening. The onset of systole was
determined as the initial rise in LV dP/dt, and the end of
systole was considered to be coincident with the peak
negative LV dP/dt. The thickening fraction was calculated
as the ratio of transmural net systolic thickening to end-
diastolic wall thickness multiplied by 100 (21).
EXPERIMENTAL PROTOCOLS. Six groups of rabbits under-
went five cycles of 5-min coronary occlusion separated by
5-min reperfusion and reperfusion for 90 min after the fifth
coronary occlusion. Saline (vehicle) was injected in the
control group, 0.6 mg/kg of cariporide in the cariporide
group, 0.3 mg/kg of glibenclamide in the glibenclamide
Abbreviations and Acronyms
EIPA 5 ethylisopropyl amiloride
IK.ATP 5 sarc-KATP channel current
LV 5 left ventricle or left ventricular
LVDP 5 left ventricular developed pressure
LV dP/dt 5 the first derivative of left ventricular
pressure
mito-KATP 5 mitochondrial KATP channel
NHE 5 Na1-H1 exchanger
sarc-KATP 5 sarcolemmal KATP channel
TTC 5 triphenyltetrazolium chloride
5-HD 5 5-hydroxydecanoate
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group, glibenclamide and cariporide in the glibenclamide/
cariporide group, 5 mg/kg of 5-HD in the 5-HD group and
5-HD and cariporide in the 5-HD/cariporide group. Cari-
poride was injected intravenously 10 min before the first
coronary occlusion, and glibenclamide and 5-HD were
administered 15 min before the ischemia. Although we did
not completely randomize all of the rabbits in this protocol,
we randomly prepared cariporide-treated and nontreated
rabbits for each KATP channel inhibitor (i.e., no inhibitor,
glibenclamide or 5-HD). At the end of the experiments, the
area at risk was determined as in experiment 1, and the
absence of infarction was confirmed by TTC staining.
Experiment 4: effects of a NHE inhibitor on mito-KATP
and sarc-KATP channels in cardiomyocytes. The activities
of mito-KATP and sarc-KATP channels were monitored in
isolated rabbit cardiomyocytes as previously reported
(12,19). Ventricular myocytes isolated from the rabbit hearts
were superfused with an external solution containing
140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2
and 10 mM HEPES (pH 7.4 with NaOH). For whole-cell
patch recordings, the internal pipette solution included
120 mM potassium glutamate, 25 mM KCl, 0.5 mM
MgCl2, 10 mM K-EGTA, 10 mM HEPES and 1 mM
MgATP (pH 7.2 with KOH). Whole cell currents were
elicited every 6 s from a holding potential of 280 mV by
two consecutive steps to 240 mV (for 100 ms) and 0 mV
(for 380 ms). Currents at 0 mV were measured 200 ms into
the pulse. Endogenous flavoprotein fluorescence was excited
with a xenon arc lamp with a band-pass filter centered at
480 nm. Emitted fluorescence was recorded at 530 nm by a
photomultiplier tube and digitized (Digidata 1200, Axon
Instruments, Foster City, California). Relative fluorescence
was averaged during the excitation window and calibrated
with the values after 2,4-dinitrophenol (taken as 100%
oxidation) and sodium cyanide exposure (taken as 100%
reduction). The effects of 100 mM diazoxide on flavoprotein
oxidation and sarc-KATP channel current (IK.ATP) were
assessed. To investigate whether NHE inhibition modulates
the mito-KATP channel activation by diazoxide, EIPA (1
mM) was added in addition to diazoxide, and flavoprotein
fluorescence and IK.ATP were determined.
Chemicals. Glibenclamide and diazoxide were purchased
from SIGMA (St. Louis, Missouri), and 5-HD and EIPA
were obtained from Research Biochemical Institute (Natick,
Massachusetts). Cariporide and HMR1098 were kindly
provided by Aventis, Deutschland Gmb, Germany.
Statistical analysis. One-way analysis of variance and two-
way repeated measures analysis of variance were used to test
intergroup differences in infarct size and those in temporal
changes of hemodynamic parameters and contractile func-
tions, respectively. Student-Newman-Keul post-hoc test was
used for multiple comparison. The difference was consid-
ered significant at p , 0.05. SigmaStat (SPSS Inc., Chi-
cago, Illinois) was used to perform the statistical analysis.
This study was conducted in strict accordance with the
guidelines for research animal use of Sapporo Medical
University and Otsuka America Pharmaceutical, Inc.
RESULTS
Experiment 1. MORTALITY OF RABBITS. A total of 28
rabbits were entered into protocol 1, and two of them (one
in the glibenclamide group and one in the glibenclamide/
cariporide group) died from irreversible ventricular fibrilla-
tion during the coronary occlusion. Thus, 26 rabbits con-
tributed to the following analysis.
HEMODYNAMIC PARAMETERS. Heart rate and mean blood
pressure were comparable among all study groups under
baseline conditions and during the coronary artery occlusion
(Table 1). Blood pressure slightly decreased after reperfu-
sion (data not shown), but there was no significant differ-
ence among the groups (p for time-dependent change ,
0.001, p for group comparison 5 0.878, p for interaction 5
0.203).
INFARCT SIZE DATA (TABLE 1). The sizes of risk areas in the
study groups were similar. Infarct size expressed as a
percentage of area at risk was reduced by cariporide as in our
previous study (2). Although glibenclamide alone did not
modify infarct size, glibenclamide blocked cariporide-
induced protection.
Experiment 2. HEMODYNAMIC DATA (TABLE 2). There
were no significant intergroup differences in heart rate,
LVDP and coronary flow under baseline conditions in both
protocols 1 and 2. In protocol 1, cariporide and 5-HD did
not change heart rate, LVDP or coronary flow. HMR1098
reduced coronary flow by 40%, presumably due to blockade
of KATP channels in the coronary vessels (p for interaction
in coronary flow comparison was ,0.001). Heart rate and
coronary flow were reduced after ischemia/reperfusion in all
study groups without intergroup differences (data not
shown). Left ventricular developed pressure also decreased
Table 1. Hemodynamic and Infarct Size Data in Experiment 1
Group n
Heart Rate (beats/min) Mean BP (mm Hg)
Area at Risk
(cm3)
Infarct
(cm3) %IS/ARBaseline Ischemia Baseline Ischemia
Control 8 275 6 12 271 6 10 88 6 6 85 6 3 0.81 6 0.10 0.46 6 0.09 52.6 6 6.0
Cariporide 8 269 6 17 263 6 21 86 6 3 81 6 6 0.80 6 0.05 0.17 6 0.04* 21.4 6 3.7*
Glib 5 270 6 25 276 6 30 91 6 3 76 6 7 0.81 6 0.08 0.40 6 0.07 48.0 6 5.2
Glib/Cariporide 5 288 6 21 293 6 18 95 6 7 88 6 4 0.89 6 0.07 0.57 6 0.08 55.2 6 4.5
*p , 0.05 vs. control. Mean 6 SEM.
BP 5 mean blood pressure; Glib 5 glibenclamide; %IS/AR 5 infarct size as a percentage of area at risk.
959JACC Vol. 37, No. 3, 2001 Miura et al.
March 1, 2001:957–63 Cardioprotection by NHE Inhibition and KATP Channels
after reperfusion, but it was significantly higher in the
cariporide-treated and EIPA-treated hearts than it was in
the controls (p for interaction ,0.001 in both protocol 1
and protocol 2).
INFARCT SIZE DATA (TABLE 2). The sizes of the area at risk
(i.e., LV mass) were comparable in study groups in both
protocols. The infarct size-limiting effect of cariporide was
abolished by 5-HD but not by HMR1098 in protocol 1.
Neither 5-HD nor HMR1098 alone significantly changed
infarct size. Similar to cariporide, EIPA reduced infarct size,
and this protection was also prevented by 5-HD in protocol 2.
Experiment 3. HEMODYNAMIC PARAMETERS (TABLE 3).
Under baseline conditions, hemodynamic parameters were
comparable among the study groups. Also, the time-courses
of the heart rate, arterial pressure, LV pressure and LV
dP/dtmax during and after ischemia/reperfusion were similar
in the study groups. The data during the first to the fourth
coronary occlusions are not shown in Table 3 for simplicity.
REGIONAL CONTRACTILE FUNCTION. The regional systolic
thickening fractions were similar under baseline conditions
in all of the study groups: 22.2 6 1.4 (SEM) % in the
control group, 22.1 6 1.6% in the cariporide group, 19.6 6
1.9% in the glibenclamide group, 17.3 6 1.5% in the
glibenclamide/cariporide group, 21.6 6 1.7% in the 5-HD
group and 24.3 6 2.9% in the 5-HD/cariporide group. The
time-courses of thickening fractions normalized as a per-
centage of baseline level are plotted in Figure 1. Cariporide
significantly improved the thickening fraction after reperfu-
sion (Fig. 1A). However, this improvement of regional
contractile function by cariporide was not detected in the
groups that received glibenclamide or 5-HD (Fig. 1, B and
C). The time courses of thickening fractions during isch-
emia and reperfusion were similar in the control, the
glibenclamide and the 5-HD groups. There were no signif-
icant differences in the sizes of areas at risk among the six
study groups (data not shown).
Experiment 4. As shown in Figure 2, diazoxide increased
mitochondrial flavoprotein oxidation to 34.8 6 2.5%, indi-
cating opening of the mito-KATP channel. However, EIPA
alone did not induce significant flavoprotein oxidation, and
it did not enhance the effect of diazoxide. Neither diazoxide
nor EIPA activated IK.ATP. On the other hand, a 5- to
10-min treatment of 2,4-dinitrophenol activated a sizable
IK.ATP.
DISCUSSION
Contribution of the KATP channel to cardioprotection by
NHE inhibition. The salient finding in this study was that
selective and nonselective blockers of the mito-KATP chan-
nel (i.e., 5-HD and glibenclamide) prevented protective
effects of NHE-1 inhibitors (i.e., cariporide and EIPA) on
infarct size and myocardial stunning. In contrast, a selective
blocker of the sarc-KATP channel, HMR1098, failed to
abolish the cardioprotection afforded by cariporide. The
dose of HMR1098 in this study (i.e., 20 mM) was
.20-fold higher than the reported IC50 to block sarc-
KATP channels in cardiomyocytes (18) and also four-fold
higher than the dose that successfully prevented shorten-
ing of action potential duration by pinacidil, a KATP
channel opener, in our buffer-perfused rabbit heart prep-
aration (22). Taken together, these findings suggest that
activity of the mito-KATP channel, not that of the
sarc-KATP channel, contributes to the myocardial toler-
ance, which was afforded by NHE-1 inhibition, against
ischemia/reperfusion injury.
In contrast with these results, glibenclamide did not
abolish infarct size limitation by NHE inhibitors (EIPA
and EMD 85131) in earlier studies using regional ischemia
in the rabbit heart in vitro (23) and in the canine heart in
situ (24). Although we do not have a clear explanation for
this discrepancy, it may be due to the differences in severity
of ischemia, reflected by smaller infarcts in untreated con-
Table 2. Hemodynamic and Infarct Size Data in Experiment 2
Treatment n
Heart Rate
(beats/min)
LVDP
(mm Hg)
CF
(ml/min)
Area at
Risk
(cm3)
Infarct
(cm3) %IS/ARBaseline
After
Tx Baseline
After
Tx Baseline
After
Tx
Protocol 1
Control 8 240 6 6 240 6 6 81 6 3 81 6 3 63 6 4 62 6 3 2.49 6 0.05 1.18 6 0.14 49.2 6 5.0
Cariporide 6 228 6 13 219 6 12 83 6 5 81 6 5 67 6 6 69 6 5 2.10 6 0.09 0.12 6 0.05† 5.5 6 2.2†
5-HD 8 222 6 7 216 6 8 85 6 3 81 6 4 71 6 5 73 6 5 2.33 6 0.18 1.47 6 0.18 61.9 6 4.1
5-HD/cariporide 5 233 6 5 222 6 5 81 6 2 74 6 1 70 6 2 78 6 4 2.37 6 0.12 1.59 6 0.20 66.3 6 5.8
HMR1098 7 228 6 6 221 6 6 78 6 3 72 6 2 68 6 6 41 6 3* 2.47 6 0.09 1.38 6 0.19 55.9 6 5.8
HMR1098/cariporide 5 224 6 9 217 6 7 82 6 3 75 6 2 65 6 3 46 6 2* 2.44 6 0.17 0.30 6 0.10† 11.7 6 3.9†
Protocol 2
Control 5 239 6 6 238 6 6 81 6 5 80 6 3 51 6 6 52 6 5 2.46 6 0.15 1.29 6 0.17 51.8 6 4.2
EIPA 4 224 6 14 220 6 10 75 6 2 75 6 2 63 6 6 60 6 8 2.30 6 0.18 0.14 6 11† 5.6 6 4.0†
5-HD 4 239 6 10 225 6 14 80 6 2 80 6 2 56 6 12 58 6 16 2.58 6 0.13 1.63 6 0.23 62.6 6 7.0
5-HD/EIPA 4 219 6 8 201 6 5 79 6 1 79 6 1 55 6 3 62 6 2 2.33 6 0.16 1.17 6 0.16 49.9 6 4.6
*p , 0.05 vs. baseline; †p , 0.05 vs. control. Mean 6 SEM.
CF 5 coronary flow; EIPA 5 ethylisopropyl amiloride; LVDP 5 left ventricular developed pressure; Tx 5 treatment; 5-HD 5 5-hydroxydecanoate; %IS/AR 5 infarct size
as a percentage of area at risk.
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trols in earlier reports. Thus, the contribution of the
mito-KATP channel to the cardioprotection by NHE inhi-
bition might depend on the experimental conditions and
preparations.
How does NHE inhibition modify the mito-KATP chan-
nel activity? It is not clear what role the opening of the
mito-KATP channel plays in the mechanism of cardiopro-
tection by NHE-1 inhibition. However, there are at least
two possibilities. First, NHE-1 inhibition may activate the
mito-KATP channel. This possibility was not supported by
our findings that EIPA neither directly activated the mito-
KATP channel nor enhanced the activation of this channel
by diazoxide in our experimental conditions (Fig. 2). How-
ever, the possibility that NHE-1 inhibition indirectly mod-
ulated the mito-KATP channel activity during ischemia
cannot be ruled out. Actually, it is a possibility that NHE-1
inhibition may modify the levels of the mito-KATP channel
regulatory factors such as long-chain acyl-CoA during
ischemia (25,26). Unfortunately, we cannot assess the in-
teraction of NHE-1 inhibition with the mito-KATP channel
in hypoxic or ischemic cardiomyocytes because flavoprotein
fluorescence can only be used to monitor mito-KATP chan-
nel activity under a good oxygenation condition.
Another possibility is that the opening of the mito-KATP
channel may help NHE-1 inhibition to suppress mitochon-
drial Ca11 overload. Ca11 overload in mitochondria has
been suggested to be one of the mechanisms of myocyte
injury, including irreversible injury (27–30). Overloading
mitochondria with Ca11 impairs ATP generation (31) and
may enhance the release of cytotoxic free radicals from the
mitochondria (32,33), which play a major role in pathogen-
esis of myocardial stunning (34). Major determinants of the
extent of mitochondrial Ca11 overload are the level of
cytosolic Ca11 and membrane potential across the mito-
chondrial inner membrane, which is a driving force for
Ca11 influx into the mitochondrial matrix (28,29,35–37).
Table 3. Hemodynamic Parameters in Experiment 3
Group n Baseline Pre-Occ 5th-Occ
5th-Rep
90 min
Heart rate (beats/min)
Control 8 259 6 10 263 6 8 256 6 14 264 6 12
Cariporide 8 276 6 11 278 6 12 271 6 10 265 6 9
Glib 6 251 6 6 253 6 8 257 6 11 266 6 14
Glib/cariporide 6 276 6 9 271 6 6 267 6 8 275 6 6
5-HD 6 261 6 14 261 6 15 265 6 14 254 6 10
5-HD/cariporide 6 245 6 6 244 6 6 241 6 6 236 6 6
Systolic blood pressure
(mm Hg)
Control 8 99 6 4 99 6 4 89 6 5 94 6 5
Cariporide 8 99 6 2 99 6 4 85 6 4* 90 6 3
Glib 6 98 6 4 101 6 4 85 6 5* 91 6 2
Glib/cariporide 6 105 6 7 109 6 7 97 6 8 94 6 5
5-HD 6 97 6 4 97 6 4 83 6 5* 94 6 4
5-HD/cariporide 6 98 6 6 97 6 6 93 6 6 91 6 5
Diastolic blood pressure
(mm Hg)
Control 8 77 6 4 76 6 4 69 6 4 71 6 4
Cariporide 8 79 6 2 76 6 4 64 6 3* 63 6 3*
Glib 6 74 6 3 73 6 2 64 6 4 67 6 3
Glib/cariporide 6 79 6 6 81 6 6 72 6 8 66 6 3*
5-HD 6 79 6 4 78 6 3 67 6 5* 74 6 4
5-HD/cariporide 6 75 6 4 76 6 3 74 6 4 68 6 5
LVEDP (mm Hg)
Control 8 4 6 1 4 6 1 11 6 2* 5 6 1
Cariporide 8 5 6 1 6 6 1 12 6 1* 6 6 1
Glib 6 3 6 1 3 6 1 12 6 3* 4 6 1
Glib/cariporide 6 4 6 1 5 6 1 11 6 1* 5 6 1
5-HD 6 4 6 1 4 6 1 12 6 2* 4 6 1
5-HD/cariporide 6 5 6 1 5 6 1 11 6 1* 4 6 1
LV dP/dt max (mm Hg/s)
Control 8 4,120 6 328 4,120 6 321 2,914 6 395* 2,995 6 293*
Cariporide 8 4,488 6 178 4,500 6 271 3,163 6 297* 3,338 6 224*
Glib 6 4,200 6 271 4,267 6 293 2,933 6 399* 3,083 6 176*
Glib/cariporide 6 4,517 6 342 4,667 6 319 3,667 6 337* 3,350 6 301*
5-HD 6 3,900 6 170 3,900 6 184 2,940 6 325* 3,280 6 227*
5-HD/cariporide 6 4,020 6 171 4,080 6 132 3,420 6 146* 3,320 6 73*
*p , 0.05 vs. baseline value. Mean 6 SEM.
Glib 5 glibenclamide; LV dP/dt max 5 maximum of first derivative of left ventricular pressure; LVEDP 5 left ventricular
end-disatolic pressure; Pre-Occ 5 immediately before the first coronary occlusion; 5-HD 5 5-hydroxydecanoate; 5th-Occ 5
5 min after the fifth coronary occlusion; 5th-Rep 90 min 5 90 min after the fifth coronary occlusion.
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Opening of the mito-KATP channel would reduce the
mitochondrial membrane potential, thus suppressing Ca11
influx into the mitochondria. This possibility was supported
by results of recent studies by Holmuhamedov et al. (36,37).
Thus, in myocytes with blocked mito-KATP channels,
lowering the cytosolic Ca11 level in ischemic myocytes by
NHE-1 inhibitors (and other agents) may not sufficiently
prevent mitochondrial Ca11 overload and cell injury when
ischemia is severe or of long duration. Consistent with this
speculation are recently reported findings (15,16) that mito-
KATP channel blockers abolish the infarct size–limiting
effect of mibefradil, a T-type Ca11 channel blocker, which
is unlikely to directly interact with the mito-KATP channel.
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